Patients With Lung Cancer Who Carry Specific HER2 Mutations May Benefit From Certain Anti-HER2 Treatments

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations. Although genetic changes cause tumor cells to make too much of the HER2 protein in up to 20% of lung cancers, mutations in the HER2 gene occur in only 1-2% of lung cancers...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lung Cancer Source Type: news